Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emi Yamada

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|November 26, 2018
Prism adaptation changes resting-state functional connectivity in the dorsal stream of visual attention networks in healthy adults: A fMRI studyKengo Tsujimoto, Katsuhiro Mizuno, Daisuke Nishida, et al.
Neuroreport|January 6, 2023
Asynchronous neural oscillations associated with subliminal affective face priming in autism spectrum disorderMutsuhide Tanaka, Emi Yamada, Takao Yamasaki, et al.
Data in Brief|January 11, 2019
Correlation between changes in functional connectivity in the dorsal attention network and the after-effects induced by prism adaptation in healthy humans: A dataset of resting-state fMRI and pointing after prism adaptationKengo Tsujimoto, Katsuhiro Mizuno, Daisuke Nishida, et al.
Plant Biotechnology (Tokyo, Japan)|June 28, 2021
<i>Mesorhizobium</i> sp. J8 can establish symbiosis with <i>Glycyrrhiza uralensis</i>, increasing glycyrrhizin productionIkuko Kusaba, Takahiro Nakao, Hiroko Maita, et al.
Annals of the Rheumatic Diseases|July 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in JapanTsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Arthritis Research & Therapy|March 14, 2020
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanTsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Arthritis Research & Therapy|June 25, 2020
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanTsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Annals of the Rheumatic Diseases|July 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|November 26, 2018
Prism adaptation changes resting-state functional connectivity in the dorsal stream of visual attention networks in healthy adults: A fMRI studyKengo Tsujimoto, Katsuhiro Mizuno, Daisuke Nishida, et al.
Neuroreport|January 6, 2023
Asynchronous neural oscillations associated with subliminal affective face priming in autism spectrum disorderMutsuhide Tanaka, Emi Yamada, Takao Yamasaki, et al.
Data in Brief|January 11, 2019
Correlation between changes in functional connectivity in the dorsal attention network and the after-effects induced by prism adaptation in healthy humans: A dataset of resting-state fMRI and pointing after prism adaptationKengo Tsujimoto, Katsuhiro Mizuno, Daisuke Nishida, et al.
Plant Biotechnology (Tokyo, Japan)|June 28, 2021
<i>Mesorhizobium</i> sp. J8 can establish symbiosis with <i>Glycyrrhiza uralensis</i>, increasing glycyrrhizin productionIkuko Kusaba, Takahiro Nakao, Hiroko Maita, et al.
Annals of the Rheumatic Diseases|July 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in JapanTsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Arthritis Research & Therapy|March 14, 2020
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanTsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Arthritis Research & Therapy|June 25, 2020
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanTsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Annals of the Rheumatic Diseases|July 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, et al.
Pageof 3